Biotechnology - Seattle, Washington, United States
Virvio is revolutionizing how millions of people get treated for common diseases like the flu. Our forthcoming products are positioned to change how drugs used to treat this and other conditions are: manufactured, distributed, stored, sold and administered. Virvio's core value proposition centers on the discovery and development of computationally-designed minibinders that mimic proven monoclonal antibodies with safer, more effective biologic alternatives. We then extend these antibody-like minibinders to treat complex global diseases with a simple pill, inhaler or cream available from local pharmacies worldwide. These improvements to the status-quo represent a step change forward that will help usher in a new era of highly-targeted protein therapeutics.